Telomir Pharmaceuticals (TELO) announced findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience ...

Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), a prominent figure in age-reversal science, disclosed significant findings from a preclinical study focusing on progeria, an uncommon genetic disorder ...

Telomir Pharmaceuticals (TELO) announced findings from a preclinical progeria lifespan study ... to a gene in humans associated with Werner Syndrome. Compared to normal nematodes, those with ...

Telomir Pharmaceuticals (NASDAQ: TELO) , an emerging leader in age-reversal science, announced significant findings from a preclinical progeria life ...

The basic genetic defect in the Hutchinson-Gilford Progeria Syndrome (progeria), a premature aging syndrome, is unknown. To investigate possible defects in hyaluronic acid (HA) metabolism in this ...